Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393488 | 0.87 | MEN1 (0.52) | MEN1KMT2AHSD17B10HTR4CHRM5 | |
| SCHEMBL18347983 | 0.84 | RAB9A (0.50) | MEN1KMT2ACYP2C19KDM4ETSHR | |
| SCHEMBL9911466 | 0.84 | RAB9A (0.54) | MEN1KMT2ACYP2C19KDM4ETSHR | |
| SCHEMBL25815852 | 0.84 | MEN1 (0.50) | MEN1KMT2AHSD17B10HTR4CHRM5 | |
| SCHEMBL25816571 | 0.84 | MEN1 (0.50) | MEN1KMT2AHSD17B10HTR4CHRM5 | |
| SCHEMBL3594497 | 0.82 | CA12 (0.54) | MEN1KMT2ACYP2C19KDM4EALDH1A1 | |
| SCHEMBL4100480 | 0.82 | CYP2C19 (0.51) | MEN1KMT2AHTR4CYP2C19TSHR | |
| SCHEMBL1021302 | 0.80 | MEN1 (0.59) | MEN1KMT2AHSD17B10HTR4CHRM5 | |
| SCHEMBL22162239 | 0.80 | TP53 (0.64) | MEN1KMT2AHSD17B10HTR4CHRM5 | |
| SCHEMBL13115955 | 0.79 | CYP2C19 (0.45) | MEN1KMT2ACYP2C19TSHRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MEN1 1209/4885KMT2A 1024/4885HSD17B10 998/4885 |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | MEN1 1360/4885KMT2A 560/4885HSD17B10 3296/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | MEN1 852/4885KMT2A 3435/4885HSD17B10 2499/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MEN1 1209/4885KMT2A 1024/4885HSD17B10 998/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | MEN1 1360/4885KMT2A 560/4885HSD17B10 3296/4885 |
| US-20090075981-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | MEN1 4458/4885KMT2A 3956/4885HSD17B10 3778/4885 |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | MEN1 4009/4885KMT2A 2730/4885HSD17B10 3369/4885 |
| US-20070060572-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | MEN1 4458/4885KMT2A 3956/4885HSD17B10 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.